Many Americans will soon be forced by their health insurance to switch from one obesity drug to another that produces less weight loss, Rebecca Robbins and Reed Abelson of The New York Times reports. CVS Health’s (CVS) Caremark made the decision to exclude Eli Lilly’s (LLY) Zepbound from its coverage in spite of research that found it resulted in more weight loss than Novo Nordisk’s (NVO) Wegovy, which will still be covered.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue